home / stock / aplt / aplt news

APLT News and Press, Applied Therapeutics Inc. From 09/17/19

Stock Information
Company Name: Applied Therapeutics Inc.
Stock Symbol: APLT
Market: NASDAQ
Website: appliedtherapeutics.com
Menu
APLT APLT Quote APLT Short APLT News APLT Articles APLT Message Board
Get APLT Alerts

News, Short Squeeze, Breakout and More Instantly...
APLT - Applied Therapeutics to Present Preclinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)

NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced presentation of data...
APLT - Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting

NEW YORK, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced presentation of data...

APLT - Applied Therapeutics Announces Initiation of Phase 3 Registrational Trial of AT-001 in Diabetic Cardiomyopathy (ARISE-HF)

NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the initiation of a Phase 3 regist...

APLT - Applied Therapeutics to Present at Baird's 2019 Global Healthcare Conference

NEW YORK, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, announced today that it will present at Baird’s 2019 Global Healthcare Co...
APLT - Applied Therapeutics Reports Second Quarter 2019 Financial Results

NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2019. ...

APLT - Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study

NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today announced the completion of the Single Ascending Dose (SAD) healthy volunteer p...

APLT - Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia

NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the initiation of a P...
APLT - Applied Therapeutics net loss widens in Q1

Applied Therapeutics ( APLT ) Q1 results : Revenues: $0; R&D Expense: $6.9M; SG&A: $1.9M; Net Loss: ($8.7M); Loss Per Share: ($1.58); Quick Assets: $14.7M (-21.4%). More news on: Applied Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ... ...

APLT - Applied Therapeutics reports Q1 results

Applied Therapeutics (NASDAQ: APLT ): Q1 GAAP EPS of -$1.58. More news on: Applied Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

APLT - Applied Therapeutics Reports First Quarter 2019 Financial Results

-Strengthened Financial Position with Recent Initial Public Offering- - Phase 1/2 Trial AT-007 in Adults with Galactosemia Expected to Start This Month - - Pivotal Phase 2/3 Trial for AT-001 in Diabetic Cardiomyopathy Expected to Start Later This Year - NEW YORK, June 21, 2019 ...
Previous 10 Next 10